BriaCell Therapeutics Closes $8.5 Million Offering
BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) has completed a significant offering that will support its work in the field of oncology. This clinical-stage biotechnology firm is recognized for its groundbreaking efforts in developing immunotherapies designed to enhance cancer treatment. In this offering, a total of 12,325,000 common shares were sold at a price of $0.69 each, generating about $8.5 million in gross proceeds.
Funding Strategies for Future Expansion
The funds raised through this offering are earmarked for strengthening BriaCell’s operational capabilities. The company intends to allocate the capital toward working capital needs as well as general corporate purposes, which will help them maintain momentum in achieving their business goals.
ThinkEquity’s Involvement
ThinkEquity has been instrumental as the sole placement agent for this offering. Their market expertise and investor relations skills were vital in helping BriaCell navigate the process effectively, ensuring a positive reception from investors.
Adherence to Regulatory Standards
The securities for this offering were issued under BriaCell's current shelf registration statement. This adherence to relevant securities regulations not only assures transparency but also underscores BriaCell’s dedication to operating within the framework of financial market laws.
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. focuses on developing innovative immunotherapies to enhance cancer treatment options. Their methodologies are backed by solid research efforts and a strong desire to provide relief to cancer patients who have limited alternatives. This commitment is evident in their ongoing clinical trials, such as the Bria-IMT™ regimen, which targets metastatic breast cancer.
Contacting BriaCell Therapeutics
For any further questions, you can reach out to BriaCell’s President & CEO, William V. Williams, at 1-888-485-6340. Alternatively, inquiries can be directed to the company’s investor relations team via email at info@briacell.com.
Frequently Asked Questions
What was the purpose of the $8.5 million offering?
The funds will be utilized for working capital and general corporate purposes to support the company's growth and progress in cancer treatment.
Who acted as the placement agent for this offering?
ThinkEquity was the sole placement agent for BriaCell's $8.5 million offering.
How many common shares were sold in the offering?
A total of 12,325,000 common shares were sold at a price of $0.69 each.
What is BriaCell Therapeutics known for?
BriaCell Therapeutics is renowned for its pioneering efforts in developing innovative immunotherapies that aim to transform cancer care.
Where can I find more information about BriaCell?
For additional details about BriaCell and its offerings, please visit their website at briacell.com.